The next generation of anti-haemophilia factor, factor VIII

Thromb Haemost 2008; 100(03): 365-366
DOI: 10.1160/TH08-07-0462

Editorial Focus

Schattauer GmbH

Long-lasting protection from spontaneous bleeding, are we there yet?

Jerry Powell

¹SOM, UC-Davis Cancer Ctr, Sacramento, California, USA

References
1 Mannucci PM, Tuddenham EG. The haemophlias--from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-1779.
2 Kim KY, Yang CH, Cho MJ. et al. Comprehensive clinical and statistical analysis of haemophlia in Korea. J Korean Med Sci 1988; 03: 107-115.
3 Manco-Johnson MJ, Abshire TC, Shapiro AD. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophlia. N Engl J Med 2007; 357: 535-544.
4 Spira J, Plyushch OP, Andreeva TA. et al. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008; 100: 429-434.
5 Baru M, Carmel-Goren L, Barenholz Y. et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005; 93: 1061-1068.
6 Spira J, Plyushch OP, Andreeva TA. et al. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006; 108: 3668-3673.
7 Powell JS, Nugent DJ, Harrison JA. et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe haemophlia A. J Thromb Haemost 2008; 06: 277-283.
8 Lee DH, Walker IR, Teitel J. et al. Effect of the factor V Leiden mutation on the clinical expression of severe haemophlia A. Thromb Haemost 2000; 83: 387-391.